Perspective Therapeutics Gestion

Gestion contrôle des critères 1/4

Le PDG Perspective Therapeutics est Thijs Spoor, nommé en Feb2023, a un mandat de 1.75 ans. La rémunération annuelle totale est $ 1.46M, composée du salaire de 34.7% et des bonus 65.3%, y compris les actions et options de la société. détient directement 0.031% des actions de la société, d'une valeur de € 237.21K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.7 ans et 1.8 ans.

Informations clés

Thijs Spoor

Directeur général

US$1.5m

Rémunération totale

Pourcentage du salaire du PDG	34.7%
Durée du mandat du directeur général	1.8yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	1.7yrs
Durée moyenne du mandat des membres du conseil d'administration	1.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Thijs Spoor a-t-elle évolué par rapport aux bénéfices de Perspective Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Rémunération vs marché: La rémunération totale de Thijs ($USD 1.46M ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 1.42M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Thijs avec les performances de l'entreprise.

PDG

Thijs Spoor (52 yo)

1.8yrs

Titularisation

US$1,458,996

Compensation

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Jonathan Hunt	CFO and Principal Financial & Accounting Officer	5.9yrs	US$1.17m	0.053% € 411.1k
Markus Puhlmann	Chief Medical Officer	1.8yrs	US$900.09k	0.20% € 1.6m
Shane Cobb	Executive Vice President of Operations	1.3yrs	pas de données	pas de données
Michael Schultz	Chief Science Officer	no data	pas de données	2.2% € 17.0m
Annie Cheng	Vice President of Investor Relations	no data	pas de données	pas de données
Andrew Bright	Executive Vice President of Brachytherapy	1.6yrs	pas de données	pas de données
Amos Hedt	Chief Business Strategy Officer	no data	pas de données	pas de données
Frances Johnson	Chief Innovation Officer	no data	pas de données	2.2% € 17.0m
David Hauser	Senior Vice President of Clinical Operations	no data	pas de données	pas de données
Steve Keefe	Senior Vice President of Clinical Development	less than a year	pas de données	pas de données

1.7yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AAJ0 n'est pas considérée comme expérimentée (ancienneté moyenne 1.7 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Robert Williamson	Independent Director	1.8yrs	US$320.06k	0.063% € 488.6k
Frank Morich	Independent Director	1.8yrs	US$320.06k	pas de données
Heidi Henson	Independent Director	1.4yrs	US$390.70k	pas de données
Lori Holmes-Woods	Chairperson of the Board	6.4yrs	US$671.73k	0.24% € 1.9m

1.8yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la AAJ0 n'est pas considéré comme expérimenté ( 1.8 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Perspective Therapeutics Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

High number of new and inexperienced directors

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought €128k worth of stock

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma Research

High number of new and inexperienced directors

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings released: US$0.024 loss per share (vs US$0.002 loss in 1Q 2023)

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Revenue size

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought €128k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.029 loss in 3Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.015 loss in 2Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.011 loss in 2Q 2022)

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings released: US$0.029 loss per share (vs US$0.016 loss in 1Q 2022)

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings released: US$0.051 loss per share (vs US$0.033 loss in FY 2021)

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen